OverviewSuggest Edit

    Synartro is a research and development company that focuses on treatments for osteoarthritis (OA). It uses a patented delivery technology in combination with existing proven drugs. Synartro's drug candidate, SYN321, is an intraarticular injection that contains diclofenac covalently bound to hyaluronan for the treatment of knee OA.

    Latest Updates

    Employees (est.) (Nov 2020)4
    Cybersecurity ratingBMore

    Synartro Financials and Metrics

    Summary Metrics

    Founding Date


    Synartro Cybersecurity Score

    Cybersecurity ratingPremium dataset



    SecurityScorecard logo

    Synartro Online and Social Media Presence

    Embed Graph

    Synartro Frequently Asked Questions

    • When was Synartro founded?

      Synartro was founded in 2011.

    • How many employees does Synartro have?

      Synartro has 4 employees.

    • Who are Synartro competitors?

      Competitors of Synartro include Kymera Therapeutics, Atara Biotherapeutics and MedDay.